Clinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
NCT03272633 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
- Lead sponsor
- Rutgers, The State University of New Jersey
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 26, 2020
- Completion date
- September 22, 2022
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, acute myeloid leukemia in remission, hematopoietic cell transplantation recipient, jak2 gene mutation, loss of chromosome 17p, mantle cell lymphoma, minimal residual disease, myelodysplastic syndrome, non-hodgkin lymphoma, plasma cell myeloma, ras family gene mutation, recurrent diffuse large b-cell lymphoma, recurrent hematologic malignancy, recurrent mature t- and nk-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, therapy-related acute myeloid leukemia, therapy-related myelodysplastic syndrome, tp53 gene mutation